Insights On CONTRACT PHARMA MANUFACTURING

  1. Resilience Capabilities Update July 2026: Fill/Finish 8/7/2026

    Learn how expanding capacity, automation, and flexible manufacturing technologies are helping biologics manufacturers meet evolving market and quality demands.

  2. Rentschler Biopharma Capabilities Update July 2026: Large Molecule 8/7/2026

    At Rentschler Biopharma, we help biopharma innovators advance complex large molecule programs from development through commercial manufacturing.

  3. FUJIFILM Biotechnologies Capabilities Update July 2026: Gene Therapy 8/7/2026

    From process development to GMP manufacturing, our teams operate as one connected system to support your cell or gene therapy through every milestone.

  4. Avid Bioservices Capabilities Update July 2026: Large Molecule 8/7/2026

    Discover how integrated development and manufacturing can reduce risk, speed timelines, and support seamless progression from early development to commercial production.

  5. Why Clinical Operations Is The Bridge To Patient Access 8/6/2026

    Autologous cell therapies depend on time-critical supply chains. Automated processing, rapid testing, and centralized data help streamline vein-to-vein delivery and expand access.

  6. Integrated Vs. Modular CDMO Strategy For Advanced Therapies 8/6/2026

    Fragmented manufacturing increases tech transfer risk, delays timelines, and causes data loss. A unified framework preserves continuity and accelerates advanced therapy delivery.

  7. Scaling MSC Therapies To GMP: The Variability Challenge 8/6/2026

    Scaling stem cell therapies hinges on managing biological variability. Learn how automated 3D processing, defined media, and robust analytics drive predictable development.

  8. Building Late-Stage Efficiency Into Biologics Development 8/6/2026

    Building late-stage efficiency early in biologics development prevents scale-up delays. Flexible platforms and risk-based validation streamline technology transfer and lower production costs.

  9. Samsung Biologics Capabilities Update July 2026: Large Molecule 8/6/2026

    We offer end-to-end CDMO services across drug substance, drug product, ADC, mRNA, and organoid modalities, with 845,000L capacity and a 99% batch success rate. Evaluate your multi-plant sourcing framework now.

  10. The Proposal Bottleneck: Why Timelines Slip And How To Prevent It 8/6/2026

    Proposal delays often start with missing information. Learn what CDMOs need to build accurate timelines, improve planning, and minimize costly scope changes.